{
    "references": [
        {
            "bibentry": "Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin 2018; 68: 394–424. PMID: 30207593",
            "process_entry": "True",
            "doi": "10.3322/caac.21492",
            "pmid": "30207593",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Wang, SY, Wang, LJ, Jiang, B, et al. Synthesis and biological evaluation of novel fluorinated anticancer agents incorporating the indolin-2-one moiety. RSC Adv 2015; 2015: 91795.",
            "process_entry": "True",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Lv, XH, Ren, ZL, Zhou, BG, et al. Discovery of N-(benzyloxy)-1,3-diphenyl-1 H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK. Bioorg Med Chem 2016; 24: 4652–9. PMID: 27515719",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2016.08.002",
            "pmid": "27515719",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Sebolt-Leopold, JS, Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937–47. PMID: 15573115",
            "process_entry": "True",
            "doi": "10.1038/nrc1503",
            "pmid": "15573115",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Villanueva, J, Vultur, A, Herlyn, M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 2011; 71: 7137–40. PMID: 22131348",
            "process_entry": "True",
            "doi": "10.1158/0008-5472.CAN-11-1243",
            "pmid": "22131348",
            "pmcid": "PMC3588168",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Pearson, G, Robinson, F, Gibson, TB, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 153–83. PMID: 11294822",
            "process_entry": "True",
            "doi": "10.1210/edrv.22.2.0428",
            "pmid": "11294822",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Redwan, IN, Dyrager, C, Solano, C, et al. Towards the development of chromone-based MEK1/2 modulators. Eur J Med Chem 2014; 85: 127–38. PMID: 25078316",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.07.018",
            "pmid": "25078316",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Chen, JN, Wang, XF, Li, T, et al. Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents. Eur J Med Chem 2016; 107: 12–25. PMID: 26560049",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.10.045",
            "pmid": "26560049",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Ribback, S, Che, L, Pilo, MG, et al. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Cell Cycle 2018; 17: 1496–512. PMID: 29965794",
            "process_entry": "True",
            "doi": "10.1080/15384101.2018.1489182",
            "pmid": "29965794",
            "pmcid": "PMC6132959",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Ciuffreda, L, Incani, UC, Steelman, LS, et al. Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. Curr Pharm Des 2014; 20: 3944–57. PMID: 24138714",
            "process_entry": "True",
            "doi": "10.2174/13816128113196660763",
            "pmid": "24138714",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Tamura, R, Yoshihara, K, Saito, T, et al. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis 2018; 7: 4. PMID: 29358619",
            "process_entry": "True",
            "doi": "10.1038/s41389-017-0018-2",
            "pmid": "29358619",
            "pmcid": "PMC5833787",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Chen, C, Shen, H, Zhang, LG, et al. Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer. Int J Mol Med 2016; 37: 1576–86. PMID: 27121963",
            "process_entry": "True",
            "doi": "10.3892/ijmm.2016.2577",
            "pmid": "27121963",
            "pmcid": "PMC4866967",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Malissen, N, Grob, JJ. Metastatic melanoma: recent therapeutic progress and future perspectives. Drugs 2018; 78: 1197–209. PMID: 30097888",
            "process_entry": "True",
            "doi": "10.1007/s40265-018-0945-z",
            "pmid": "30097888",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Elsayed, HE, Ebrahim, HY, Haggag, EG, et al. Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies. Bioorg Med Chem 2017; 25: 6297–312. PMID: 29066046",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2017.09.033",
            "pmid": "29066046",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Sanchez, JN, Wang, T, Cohen, MS. BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs 2018; 78: 549–66. PMID: 29488071",
            "process_entry": "True",
            "doi": "10.1007/s40265-018-0884-8",
            "pmid": "29488071",
            "pmcid": "PMC6080616",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Jaenne, PA, Shaw, AT, Pereira, JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14: 38–47. PMID: 23200175",
            "process_entry": "True",
            "doi": "10.1016/s1470-2045(12)70489-8",
            "pmid": "23200175",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Jänne, PA, van den Heuvel, MM, Barlesi, F, et al. Selumetinib plus docetaxel compared with docetaxel alone and progressionfree survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial. JAMA-J Am Med Assoc 2017; 317: 1844–53.",
            "process_entry": "True",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Dummer, R, Ascierto, PA, Gogas, HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19: 1315–27. PMID: 30219628",
            "process_entry": "True",
            "doi": "10.1016/s1470-2045(18)30497-2",
            "pmid": "30219628",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Resources for Information on Approved Drugs Trametinib and Dabrafenib [Internet]. Silver Spring (MD): US Food & Drug Administration (FDA); 2017. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs [cited 20 Feb 2019].",
            "process_entry": "True",
            "url": "http://www.fda.gov/drugs/informationondrugs/approveddrugs [cited 20 Feb 2019].",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Sharma, SH, Thulasingam, S, Nagarajan, S. Terpenoids as anti-colon cancer agents –a comprehensive review on its mechanistic perspectives. Eur J Pharmacol 2017; 795: 169–78. PMID: 27940056",
            "process_entry": "True",
            "doi": "10.1016/j.ejphar.2016.12.008",
            "pmid": "27940056",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Huang, M, Lu, JJ, Huang, MQ, et al. Terpenoids: natural products for cancer therapy. Expert Opin Investig Drugs 2012; 21: 1801–18.",
            "process_entry": "True",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Hussain, H, Green, IR, Ali, I, et al. Ursolic acid derivatives for pharmaceutical use: a patent review (2012–2016). Expert Opin Ther Pat 2017; 27: 1061–72. PMID: 28637397",
            "process_entry": "True",
            "doi": "10.1080/13543776.2017.1344219",
            "pmid": "28637397",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Song, GP, Shen, XT, Li, SM, et al. Structure-activity relationships of 3-O-β-chacotriosyl ursolic acid derivatives as novel H5N1 entry inhibitors. Eur J Med Chem 2015; 93: 431–42. PMID: 25728024",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.02.029",
            "pmid": "25728024",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Yang, HM, Yin, ZQ, Zhao, MG, et al. Pentacyclic triterpenoids from Cyclocarya paliurus and their antioxidant activities in FFA-induced HepG2 steatosis cells. Phytochemistry 2018; 151: 119–27. PMID: 29679877",
            "process_entry": "True",
            "doi": "10.1016/j.phytochem.2018.03.010",
            "pmid": "29679877",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Ishikawa, T, Donatini, RDS, Diaz, IEC, et al. Evaluation of gastroprotective activity of Plinia edulis (Vell.) Sobral (Myrtaceae) leaves in rats. J Ethnopharmacol 2008; 118: 527–9. PMID: 18583075",
            "process_entry": "True",
            "doi": "10.1016/j.jep.2008.05.007",
            "pmid": "18583075",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Ramos-Hryb, AB, Pazini, FL, Kaster, MP, et al. Therapeutic potential of ursolic acid to manage neurodegenerative and psychiatric diseases. CNS Drugs 2017; 31: 1029–41. PMID: 29098660",
            "process_entry": "True",
            "doi": "10.1007/s40263-017-0474-4",
            "pmid": "29098660",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Xu, HT, Tang, HY, Feng, HJ, et al. Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide. Eur J Med Chem 2014; 73: 46–55. PMID: 24378709",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2013.11.044",
            "pmid": "24378709",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Abbas, SH, El-Hafeez, AAA, Shoman, ME, et al. New quinoline/chalcone hybrids as anti-cancer agents: design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity. Bioorg Chem 2019; 82: 360–77. PMID: 30428415",
            "process_entry": "True",
            "doi": "10.1016/j.bioorg.2018.10.064",
            "pmid": "30428415",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Altıntop, MD, Sever, B, Çiftçi, GA, et al. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors. Eur J Med Chem 2018; 155: 905–24. PMID: 29966916",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.06.049",
            "pmid": "29966916",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "Bajaj, S, Roy, PP, Singh, J. Synthesis, thymidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents. Comput Biol Chem 2018; 76: 151–60. PMID: 30015176",
            "process_entry": "True",
            "doi": "10.1016/j.compbiolchem.2018.05.013",
            "pmid": "30015176",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Hu, Y, Li, CY, Wang, XM, et al. 1,3,4-Thiadiazole: synthesis, reactions, and applications in medicinal, agricultural, and materials chemistry. Chem Rev 2014; 114: 5572–610. PMID: 24716666",
            "process_entry": "True",
            "doi": "10.1021/cr400131u",
            "pmid": "24716666",
            "xmlid": "CIT0031"
        },
        {
            "bibentry": "Jakovljević, K, Joksović, MD, Matić, IZ, et al. Novel 1,3,4-thiadiazole-chalcone hybrids containing catechol moiety: synthesis, antioxidant activity, cytotoxicity and DNA interaction studies. Med Chem Commun 2018; 9: 1679–97.",
            "process_entry": "True",
            "xmlid": "CIT0032"
        },
        {
            "bibentry": "Kamath, PR, Sunil, D, Joseph, MM, et al. Indole-coumarin-thiadiazole hybrids: an appraisal of their IMF-7 cell growth inhibition, apoptotic, antimetastatic and computational Bcl-2 binding potential. Eur J Med Chem 2017; 136: 442–51. PMID: 28525842",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.05.032",
            "pmid": "28525842",
            "xmlid": "CIT0033"
        },
        {
            "bibentry": "Gu, W, Jin, XY, Li, DD, et al. Design, synthesis and in vitro anticancer activity of novel quinoline and oxadiazole derivatives of ursolic acid. Bioorg Med Chem Lett 2017; 27: 4128–32. PMID: 28733083",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2017.07.033",
            "pmid": "28733083",
            "xmlid": "CIT0034"
        },
        {
            "bibentry": "Gnoatto, SCB, Dassonville-Klimpt, A, Da Nascimento, S, et al. Evaluation of ursolic acid isolated from Ilex paraguariensis and derivatives on aromatase inhibition. Eur J Med Chem 2008; 43: 1865–77. PMID: 18192087",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2007.11.021",
            "pmid": "18192087",
            "xmlid": "CIT0035"
        },
        {
            "bibentry": "Su, CC, Chen, JY, Din, ZH, et al. 13-acetoxysarcocrassolide induces apoptosis on human gastric carcinoma cells through mitochondria-related apoptotic pathways: p38/JNK activation and PI3K/AKT suppression. Mar Drugs 2014; 12: 5295–315. PMID: 25342459",
            "process_entry": "True",
            "doi": "10.3390/md12105295",
            "pmid": "25342459",
            "pmcid": "PMC4210900",
            "xmlid": "CIT0036"
        },
        {
            "bibentry": "Song, Y, Xin, Z, Wan, Y, et al. Synthesis and anticancer activity of some novel indolo[3,2-b]andrographolide derivatives as apoptosis-inducing agents. Eur J Med Chem 2015; 90: 695–706. PMID: 25506809",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.12.017",
            "pmid": "25506809",
            "xmlid": "CIT0037"
        },
        {
            "bibentry": "Li, YC, Gu, ZY, Zhang, C, et al. Synthesis, characterization and ROS-mediated antitumor effects of palladium(II) complexes of curcuminoids. Eur J Med Chem 2018; 144: 662–71. PMID: 29289889",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.12.027",
            "pmid": "29289889",
            "xmlid": "CIT0038"
        },
        {
            "bibentry": "Schrödinger Suite 2015-1, Maestro 10.1. [Software]. New York (NY): Schrödinger LLC; 2015 Available from: http://www.schrodinger.com/Products/glide.html",
            "process_entry": "True",
            "url": "http://www.schrodinger.com/Products/glide.html",
            "xmlid": "CIT0039"
        },
        {
            "bibentry": "Song, Z, Chen, CP, Liu, J, et al. Design, synthesis, and biological evaluation of (2 E)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)acetate derivatives as anti-proliferative agents through ROS-induced cell apoptosis. Eur J Med Chem 2016; 124: 809–19. PMID: 27643639",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2016.09.005",
            "pmid": "27643639",
            "xmlid": "CIT0040"
        },
        {
            "bibentry": "Martinou, JC, Youle, RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011; 21: 92–101. PMID: 21763611",
            "process_entry": "True",
            "doi": "10.1016/j.devcel.2011.06.017",
            "pmid": "21763611",
            "pmcid": "PMC3156409",
            "xmlid": "CIT0041"
        },
        {
            "bibentry": "Circu, ML, Aw, TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010; 48: 749–62. PMID: 20045723",
            "process_entry": "True",
            "doi": "10.1016/j.freeradbiomed.2009.12.022",
            "pmid": "20045723",
            "pmcid": "PMC2823977",
            "xmlid": "CIT0042"
        },
        {
            "bibentry": "Rogalska, A, Marczak, A, Gajek, A, et al. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol In Vitro 2013; 27: 239–49. PMID: 22995584",
            "process_entry": "True",
            "doi": "10.1016/j.tiv.2012.09.006",
            "pmid": "22995584",
            "xmlid": "CIT0043"
        },
        {
            "bibentry": "Kalaivani, P, Saranya, S, Poornima, P, et al. Biological evaluation of new nickel (II) metallates: synthesis, DNA/protein binding and mitochondrial mediated apoptosis in human lung cancer cells (A549) via ROS hypergeneration and depletion of cellular antioxidant pool. Eur J Med Chem 2014; 82: 584–99. PMID: 24946146",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.05.075",
            "pmid": "24946146",
            "xmlid": "CIT0044"
        },
        {
            "bibentry": "Huang, XC, Huang, RZ, Liao, ZX, et al. Synthesis and pharmacological evaluation of dehydroabietic acid thiourea derivatives containing bisphosphonate moiety as an inducer of apoptosis. Eur J Med Chem 2016; 108: 381–91. PMID: 26706349",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.12.008",
            "pmid": "26706349",
            "xmlid": "CIT0045"
        },
        {
            "bibentry": "Fang, ZX, Liao, PC, Yang, YL, et al. Synthesis and biological evaluation of polyenylpyrrole derivatives as anticancer agents acting through caspases-dependent apoptosis. J Med Chem 2010; 53: 7967–78. PMID: 20964408",
            "process_entry": "True",
            "doi": "10.1021/jm100619x",
            "pmid": "20964408",
            "xmlid": "CIT0046"
        },
        {
            "bibentry": "Zhang, SS, Nie, SP, Huang, DF, et al. A novel polysaccharide from Ganoderma atrum exerts antitumor activity by activating mitochondria-mediated apoptotic pathway and boosting the immune system. J Agric Food Chem 2014; 62: 1581–9. PMID: 24506418",
            "process_entry": "True",
            "doi": "10.1021/jf4053012",
            "pmid": "24506418",
            "xmlid": "CIT0047"
        },
        {
            "bibentry": "Liu, DZ, Tian, Z, Yan, ZH, et al. Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors. Bioorg Med Chem 2013; 21: 2960–7. PMID: 23632366",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2013.03.075",
            "pmid": "23632366",
            "xmlid": "CIT0048"
        },
        {
            "bibentry": "Vickers, CJ, Gonzalez-Paez, GE, Wolan, DW. Selective detection and inhibition of active caspase-3 in cells with optimized peptides. J Am Chem Soc 2013; 135: 12869–76. PMID: 23915420",
            "process_entry": "True",
            "doi": "10.1021/ja406399r",
            "pmid": "23915420",
            "xmlid": "CIT0049"
        },
        {
            "bibentry": "Boutros, T, Chevet, E, Metrakos, P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 2008; 60: 261–310. PMID: 18922965",
            "process_entry": "True",
            "doi": "10.1124/pr.107.00106",
            "pmid": "18922965",
            "xmlid": "CIT0050"
        },
        {
            "bibentry": "Davies, BR, Logie, A, McKay, JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6: 2209–19. PMID: 17699718",
            "process_entry": "True",
            "doi": "10.1158/1535-7163.mct-07-0231",
            "pmid": "17699718",
            "xmlid": "CIT0051"
        },
        {
            "bibentry": "Hagemann, C, Blank, JL. The ups and downs of MEK kinase interactions. Cell Signal 2001; 13: 863–75. PMID: 11728826",
            "process_entry": "True",
            "doi": "10.1016/s0898-6568(01)00220-0",
            "pmid": "11728826",
            "xmlid": "CIT0052"
        },
        {
            "bibentry": "Lorusso, PM, Adjei, AA, Varterasian, M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281–93. PMID: 16009947",
            "process_entry": "True",
            "doi": "10.1200/jco.2005.14.415",
            "pmid": "16009947",
            "xmlid": "CIT0053"
        },
        {
            "bibentry": "Iijima, M, Kubota, Y, Sawa, R, et al. A guanine derivative as a new MEK inhibitor produced by Streptomyces sp. MK63-43F2. J Antibiot 2018; 71: 135–8.",
            "process_entry": "True",
            "xmlid": "CIT0054"
        },
        {
            "bibentry": "Tan, N, Wong, M, Nannini, MA, et al. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 Kinase inhibition in lung and pancreatic tumor models. Mol Cancer Ther 2013; 12: 853–64. PMID: 23475955",
            "process_entry": "True",
            "doi": "10.1158/1535-7163.mct-12-0949",
            "pmid": "23475955",
            "xmlid": "CIT0055"
        },
        {
            "bibentry": "Discovery Studio Visualizer version 18.1.0 [Software]. San Diego (CA): Accelrys Software; 2017 Available from: http://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/visualization-download.php.",
            "process_entry": "True",
            "url": "http://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/visualization-download.php.",
            "xmlid": "CIT0056"
        },
        {
            "bibentry": "Dehan, E, Bassermann, F, Guardavaccaro, D, et al. betaTrCP-and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009; 33: 109–16. PMID: 19150432",
            "process_entry": "True",
            "doi": "10.1016/j.molcel.2008.12.020",
            "pmid": "19150432",
            "pmcid": "PMC2655121",
            "xmlid": "CIT0057"
        },
        {
            "bibentry": "Degterev, A, Yuan, JY. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008; 9: 378–90. PMID: 18414491",
            "process_entry": "True",
            "doi": "10.1038/nrm2393",
            "pmid": "18414491",
            "xmlid": "CIT0058"
        }
    ],
    "localid": "MED-31072147",
    "doi": "10.1080/14756366.2019.1605364",
    "pmid": "10.1080/14756366.2019.1605364",
    "pmcid": "31072147",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31072147/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),122,162)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),285,220)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "CIT0003",
                "rp_string": "3",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,236)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0004",
                "rp_string": "4",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),496,160)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0005",
                "rp_string": "5",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),496,160)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 8,
                "xref_id": "CIT0006",
                "rp_string": "6–8",
                "pl_string": "6–8",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1403,167)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 6,
                "xref_id": "",
                "pl_string": "6–8",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1403,167)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 7,
                "xref_id": "",
                "pl_string": "6–8",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1403,167)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 8,
                "xref_id": "CIT0006",
                "rp_string": "6–8",
                "pl_string": "6–8",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1403,167)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 9,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1571,220)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In recent years, a number of key signalling pathways, membrane receptors, kinases, transcriptional factors, and other biological macromolecules have been identified, which results in further understanding on the pathogenesis of cancer3. Development of small molecular drugs specially targeting the key proteins in the signalling pathways relevant to tumourigenesis and tumour growth may provide opportunities to find new targeted anticancer agents with significantly improved therapeutic index. The mitogen-activated protein kinase (MAPK) signalling pathway is one of the most important signalling pathways correlated with targeted cancer therapeutics4,5. Rat sarcoma small GTPase/rapidly accelerated fibrosarcoma kinase/ MAPK/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signalling pathway (i.e. MAPK pathway) transduces signals from cell surface receptors to the nucleus through a series of phosphorylation events (Figure 1(a)). Once a growth factor binds to its respective receptor, the signalling pathway is activated. The receptor tyrosine kinase (RTK) transmits the extracellular signal into the cell via the adaptor protein GRB2 which subsequently activates the membrane-bound GTPase (Ras) with the help of nucleotide exchange factor SOS. Activated Ras then initiates the signalling cascade of MAP kinases. Finally, activated ERK can phosphorylate its cytosolic or nuclear effectors. The latter results in changes to transcription and ultimately promotes many cellular processes including proliferation, differentiation, survival, and angiogenesis6–8. The dysregulation of MAPK pathway is strongly associated with many human cancers, such as hepatocellular carcinoma (HCC)9, non-small cell lung cancer (NSCLC)10, cervical carcinoma11, prostate carcinoma12, and melanoma13. Therefore, the signalling pathway offers attractive targets for the development of anticancer agents.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 10,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1571,220)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In recent years, a number of key signalling pathways, membrane receptors, kinases, transcriptional factors, and other biological macromolecules have been identified, which results in further understanding on the pathogenesis of cancer3. Development of small molecular drugs specially targeting the key proteins in the signalling pathways relevant to tumourigenesis and tumour growth may provide opportunities to find new targeted anticancer agents with significantly improved therapeutic index. The mitogen-activated protein kinase (MAPK) signalling pathway is one of the most important signalling pathways correlated with targeted cancer therapeutics4,5. Rat sarcoma small GTPase/rapidly accelerated fibrosarcoma kinase/ MAPK/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signalling pathway (i.e. MAPK pathway) transduces signals from cell surface receptors to the nucleus through a series of phosphorylation events (Figure 1(a)). Once a growth factor binds to its respective receptor, the signalling pathway is activated. The receptor tyrosine kinase (RTK) transmits the extracellular signal into the cell via the adaptor protein GRB2 which subsequently activates the membrane-bound GTPase (Ras) with the help of nucleotide exchange factor SOS. Activated Ras then initiates the signalling cascade of MAP kinases. Finally, activated ERK can phosphorylate its cytosolic or nuclear effectors. The latter results in changes to transcription and ultimately promotes many cellular processes including proliferation, differentiation, survival, and angiogenesis6–8. The dysregulation of MAPK pathway is strongly associated with many human cancers, such as hepatocellular carcinoma (HCC)9, non-small cell lung cancer (NSCLC)10, cervical carcinoma11, prostate carcinoma12, and melanoma13. Therefore, the signalling pathway offers attractive targets for the development of anticancer agents.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 11,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1571,220)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In recent years, a number of key signalling pathways, membrane receptors, kinases, transcriptional factors, and other biological macromolecules have been identified, which results in further understanding on the pathogenesis of cancer3. Development of small molecular drugs specially targeting the key proteins in the signalling pathways relevant to tumourigenesis and tumour growth may provide opportunities to find new targeted anticancer agents with significantly improved therapeutic index. The mitogen-activated protein kinase (MAPK) signalling pathway is one of the most important signalling pathways correlated with targeted cancer therapeutics4,5. Rat sarcoma small GTPase/rapidly accelerated fibrosarcoma kinase/ MAPK/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signalling pathway (i.e. MAPK pathway) transduces signals from cell surface receptors to the nucleus through a series of phosphorylation events (Figure 1(a)). Once a growth factor binds to its respective receptor, the signalling pathway is activated. The receptor tyrosine kinase (RTK) transmits the extracellular signal into the cell via the adaptor protein GRB2 which subsequently activates the membrane-bound GTPase (Ras) with the help of nucleotide exchange factor SOS. Activated Ras then initiates the signalling cascade of MAP kinases. Finally, activated ERK can phosphorylate its cytosolic or nuclear effectors. The latter results in changes to transcription and ultimately promotes many cellular processes including proliferation, differentiation, survival, and angiogenesis6–8. The dysregulation of MAPK pathway is strongly associated with many human cancers, such as hepatocellular carcinoma (HCC)9, non-small cell lung cancer (NSCLC)10, cervical carcinoma11, prostate carcinoma12, and melanoma13. Therefore, the signalling pathway offers attractive targets for the development of anticancer agents.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1571,220)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In recent years, a number of key signalling pathways, membrane receptors, kinases, transcriptional factors, and other biological macromolecules have been identified, which results in further understanding on the pathogenesis of cancer3. Development of small molecular drugs specially targeting the key proteins in the signalling pathways relevant to tumourigenesis and tumour growth may provide opportunities to find new targeted anticancer agents with significantly improved therapeutic index. The mitogen-activated protein kinase (MAPK) signalling pathway is one of the most important signalling pathways correlated with targeted cancer therapeutics4,5. Rat sarcoma small GTPase/rapidly accelerated fibrosarcoma kinase/ MAPK/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signalling pathway (i.e. MAPK pathway) transduces signals from cell surface receptors to the nucleus through a series of phosphorylation events (Figure 1(a)). Once a growth factor binds to its respective receptor, the signalling pathway is activated. The receptor tyrosine kinase (RTK) transmits the extracellular signal into the cell via the adaptor protein GRB2 which subsequently activates the membrane-bound GTPase (Ras) with the help of nucleotide exchange factor SOS. Activated Ras then initiates the signalling cascade of MAP kinases. Finally, activated ERK can phosphorylate its cytosolic or nuclear effectors. The latter results in changes to transcription and ultimately promotes many cellular processes including proliferation, differentiation, survival, and angiogenesis6–8. The dysregulation of MAPK pathway is strongly associated with many human cancers, such as hepatocellular carcinoma (HCC)9, non-small cell lung cancer (NSCLC)10, cervical carcinoma11, prostate carcinoma12, and melanoma13. Therefore, the signalling pathway offers attractive targets for the development of anticancer agents.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 13,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1571,220)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In recent years, a number of key signalling pathways, membrane receptors, kinases, transcriptional factors, and other biological macromolecules have been identified, which results in further understanding on the pathogenesis of cancer3. Development of small molecular drugs specially targeting the key proteins in the signalling pathways relevant to tumourigenesis and tumour growth may provide opportunities to find new targeted anticancer agents with significantly improved therapeutic index. The mitogen-activated protein kinase (MAPK) signalling pathway is one of the most important signalling pathways correlated with targeted cancer therapeutics4,5. Rat sarcoma small GTPase/rapidly accelerated fibrosarcoma kinase/ MAPK/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signalling pathway (i.e. MAPK pathway) transduces signals from cell surface receptors to the nucleus through a series of phosphorylation events (Figure 1(a)). Once a growth factor binds to its respective receptor, the signalling pathway is activated. The receptor tyrosine kinase (RTK) transmits the extracellular signal into the cell via the adaptor protein GRB2 which subsequently activates the membrane-bound GTPase (Ras) with the help of nucleotide exchange factor SOS. Activated Ras then initiates the signalling cascade of MAP kinases. Finally, activated ERK can phosphorylate its cytosolic or nuclear effectors. The latter results in changes to transcription and ultimately promotes many cellular processes including proliferation, differentiation, survival, and angiogenesis6–8. The dysregulation of MAPK pathway is strongly associated with many human cancers, such as hepatocellular carcinoma (HCC)9, non-small cell lung cancer (NSCLC)10, cervical carcinoma11, prostate carcinoma12, and melanoma13. Therefore, the signalling pathway offers attractive targets for the development of anticancer agents.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),166,134)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),301,226)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),301,226)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),679,146)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),913,178)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 19,
                "xref_id": "CIT0017",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1092,212)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 20,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1305,243)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 21,
                "xref_id": "CIT0019",
                "rp_string": "19",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1700,160)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 22,
                "xref_id": "CIT0020",
                "rp_string": "20",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),178,109)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 23,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),288,134)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0022",
                "rp_string": "22–26",
                "pl_string": "22–26",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),522,325)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 25,
                "xref_id": "",
                "pl_string": "22–26",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),522,325)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 26,
                "xref_id": "",
                "pl_string": "22–26",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),522,325)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 27,
                "xref_id": "",
                "pl_string": "22–26",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),522,325)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 28,
                "xref_id": "",
                "pl_string": "22–26",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),522,325)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0022",
                "rp_string": "22–26",
                "pl_string": "22–26",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),522,325)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 30,
                "xref_id": "CIT0027",
                "rp_string": "27",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),1,303)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 31,
                "xref_id": "CIT0028",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),420,159)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 32,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),580,171)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),752,305)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0030",
                "rp_string": "30",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),752,305)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 35,
                "xref_id": "CIT0031",
                "rp_string": "31",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),1058,192)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 36,
                "xref_id": "CIT0032",
                "rp_string": "32",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),1251,104)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 37,
                "xref_id": "CIT0033",
                "rp_string": "33",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),1251,104)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 38,
                "xref_id": "CIT0032",
                "rp_string": "32",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),1356,147)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 39,
                "xref_id": "CIT0034",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[1]/p[5]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[5]),1684,313)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 40,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[2]/sec[2]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/p),440,93)",
                "containers_title": [
                    "Experimental",
                    "The preparation of compound 2"
                ]
            }
        ],
        [
            {
                "n_rp": 41,
                "xref_id": "CIT0034",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p[1]/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p[1]),1,70)",
                "containers_title": [
                    "Experimental",
                    "2.3. General procedures for the synthesis of compounds 3a–d"
                ]
            }
        ],
        [
            {
                "n_rp": 42,
                "xref_id": "CIT0034",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p[2]/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p[2]),604,70)",
                "containers_title": [
                    "Experimental",
                    "2.3. General procedures for the synthesis of compounds 3a–d"
                ]
            }
        ],
        [
            {
                "n_rp": 43,
                "xref_id": "CIT0036",
                "rp_string": "36",
                "rp_xpath": "/article/body/sec[2]/sec[7]/sec[3]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[7]/sec[3]/p),1,98)",
                "containers_title": [
                    "Experimental",
                    "Biological assay",
                    "Cell apoptosis analysis"
                ]
            }
        ],
        [
            {
                "n_rp": 44,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[2]/sec[7]/sec[4]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[7]/sec[4]/p),1,108)",
                "containers_title": [
                    "Experimental",
                    "Biological assay",
                    "Cell cycle analysis"
                ]
            }
        ],
        [
            {
                "n_rp": 45,
                "xref_id": "CIT0038",
                "rp_string": "38",
                "rp_xpath": "/article/body/sec[2]/sec[7]/sec[5]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[7]/sec[5]/p),120,104)",
                "containers_title": [
                    "Experimental",
                    "Biological assay",
                    "ROS generation assay"
                ]
            }
        ],
        [
            {
                "n_rp": 46,
                "xref_id": "CIT0039",
                "rp_string": "39",
                "rp_xpath": "/article/body/sec[2]/sec[8]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[8]/p),1,123)",
                "containers_title": [
                    "Experimental",
                    "Molecular docking"
                ]
            }
        ],
        [
            {
                "n_rp": 47,
                "xref_id": "CIT0034",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),1,108)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 48,
                "xref_id": "CIT0040",
                "rp_string": "40",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[4]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[4]/p),93,287)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "ROS generation assay"
                ]
            }
        ],
        [
            {
                "n_rp": 49,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[4]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[4]/p),1010,158)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "ROS generation assay"
                ]
            }
        ],
        [
            {
                "n_rp": 50,
                "xref_id": "CIT0041",
                "rp_string": "41",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[5]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[5]/p[1]),1,217)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "JC-1 mitochondrial membrane potential assay"
                ]
            }
        ],
        [
            {
                "n_rp": 51,
                "xref_id": "CIT0042",
                "rp_string": "42",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[5]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[5]/p[1]),219,208)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "JC-1 mitochondrial membrane potential assay"
                ]
            }
        ],
        [
            {
                "n_rp": 52,
                "xref_id": "CIT0043",
                "rp_string": "43",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[5]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[5]/p[1]),743,137)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "JC-1 mitochondrial membrane potential assay"
                ]
            }
        ],
        [
            {
                "n_rp": 53,
                "xref_id": "CIT0044",
                "rp_string": "44",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[5]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[5]/p[2]),484,111)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "JC-1 mitochondrial membrane potential assay"
                ]
            }
        ],
        [
            {
                "n_rp": 54,
                "xref_id": "CIT0045",
                "rp_string": "45",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[6]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[6]/p[1]),200,189)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "Western blot analysis"
                ]
            }
        ],
        [
            {
                "n_rp": 55,
                "xref_id": "CIT0046",
                "rp_string": "46",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[6]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[6]/p[1]),390,171)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "Western blot analysis"
                ]
            }
        ],
        [
            {
                "n_rp": 56,
                "xref_id": "CIT0047",
                "rp_string": "47",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[6]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[6]/p[2]),306,150)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "Western blot analysis"
                ]
            }
        ],
        [
            {
                "n_rp": 57,
                "xref_id": "CIT0048",
                "rp_string": "48",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[6]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[6]/p[2]),881,206)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "Western blot analysis"
                ]
            }
        ],
        [
            {
                "n_rp": 58,
                "xref_id": "CIT0049",
                "rp_string": "49",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[6]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[6]/p[2]),881,206)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "Western blot analysis"
                ]
            }
        ],
        [
            {
                "n_rp": 59,
                "xref_id": "CIT0050",
                "rp_string": "50",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[7]/p[1]),1,180)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "MEK inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 60,
                "xref_id": "CIT0051",
                "rp_string": "51",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[7]/p[1]),182,161)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "MEK inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 61,
                "xref_id": "CIT0052",
                "rp_string": "52",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[7]/p[1]),182,161)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "MEK inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 62,
                "xref_id": "CIT0053",
                "rp_string": "53",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[7]/p[1]),551,298)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "MEK inhibitory activity"
                ],
                "pl_string": "The Raf/MEK/ERK pathway is the downstream of Ras activation, and the abnormal expression or phosphorylation of the associated proteins is essential for cancer cell proliferation50. In this pathway, MEK kinase is an important anticancer target because of its key roles in regulating the cancer cell apoptosis and oncogenic transformation51,52. Among MEK proteins, MEK1 and MEK2 are known as substrate-specific kinases which phosphorylate their downstream kinase ERK1/2. Upon inhibition, the phosphorylation of ERK1/2 will be significantly suppressed. As inhibition of the phosphorylation of ERK has been proposed as a primary biomarker of MEK inhibitory activity53, the MEK1 inhibitory activities of some compounds exhibiting good cytotoxicity were examined by an in vitro kinase assay of recombinant MEK1 using GST-ERK2 (Inactive) as a substrate54. The IC50 values of the tested compounds against MEK1 are shown in Table 2.",
                "pl_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[1]"
            },
            {
                "n_rp": 63,
                "xref_id": "CIT0054",
                "rp_string": "54",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[7]/p[1]),551,298)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "MEK inhibitory activity"
                ],
                "pl_string": "The Raf/MEK/ERK pathway is the downstream of Ras activation, and the abnormal expression or phosphorylation of the associated proteins is essential for cancer cell proliferation50. In this pathway, MEK kinase is an important anticancer target because of its key roles in regulating the cancer cell apoptosis and oncogenic transformation51,52. Among MEK proteins, MEK1 and MEK2 are known as substrate-specific kinases which phosphorylate their downstream kinase ERK1/2. Upon inhibition, the phosphorylation of ERK1/2 will be significantly suppressed. As inhibition of the phosphorylation of ERK has been proposed as a primary biomarker of MEK inhibitory activity53, the MEK1 inhibitory activities of some compounds exhibiting good cytotoxicity were examined by an in vitro kinase assay of recombinant MEK1 using GST-ERK2 (Inactive) as a substrate54. The IC50 values of the tested compounds against MEK1 are shown in Table 2.",
                "pl_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[1]"
            }
        ],
        [
            {
                "n_rp": 64,
                "xref_id": "CIT0055",
                "rp_string": "55",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[7]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[7]/p[4]),145,227)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "MEK inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 65,
                "xref_id": "CIT0039",
                "rp_string": "39",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[8]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[8]/p[1]),219,236)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "Molecular docking"
                ]
            }
        ],
        [
            {
                "n_rp": 66,
                "xref_id": "CIT0055",
                "rp_string": "55",
                "rp_xpath": "/article/body/sec[3]/sec[3]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/p),1058,85)",
                "containers_title": [
                    "Results and discussion",
                    "Possible anticancer mechanisms of compound 4d"
                ]
            }
        ],
        [
            {
                "n_rp": 67,
                "xref_id": "CIT0057",
                "rp_string": "57",
                "rp_xpath": "/article/body/sec[3]/sec[3]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/p),1058,85)",
                "containers_title": [
                    "Results and discussion",
                    "Possible anticancer mechanisms of compound 4d"
                ]
            }
        ],
        [
            {
                "n_rp": 68,
                "xref_id": "CIT0055",
                "rp_string": "55",
                "rp_xpath": "/article/body/sec[3]/sec[3]/p/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/p),1324,217)",
                "containers_title": [
                    "Results and discussion",
                    "Possible anticancer mechanisms of compound 4d"
                ]
            }
        ],
        [
            {
                "n_rp": 69,
                "xref_id": "CIT0058",
                "rp_string": "58",
                "rp_xpath": "/article/body/sec[3]/sec[3]/p/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/p),1324,217)",
                "containers_title": [
                    "Results and discussion",
                    "Possible anticancer mechanisms of compound 4d"
                ]
            }
        ]
    ]
}